Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Austin, TX, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Patient Simulator Market Size, Trends and Insights By Product Type (Adult...
-
ITHACA, NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- SimpliFed, the telehealth service dedicated to democratizing access to inclusive infant feeding support, announced that it has launched a...
-
ITHACA, NY, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SimpliFed, the telehealth platform dedicated to infant nutrition and parental support, announced today that in addition to serving TRICARE...
-
Selbyville, Delaware, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The extracorporeal membrane oxygenation market value is set to reach USD 639 million by 2032, according to a new research report by Global...
-
LAS VEGAS, NEVADA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- nfant® today unveiled the nfant Thrive Feeding System, its parent-focused connected home nursery product line that applies cutting-edge...
-
ITHACA, NY, Aug. 17, 2022 (GLOBE NEWSWIRE) -- SimpliFed, the maternal telehealth platform dedicated to infant nutrition and parental support, announced that the company’s virtual baby feeding...
-
McHenry, IL, May 05, 2022 (GLOBE NEWSWIRE) -- Medela, the most trusted breast pump brand*, has announced a partnership with Expectful, a holistic maternal health platform for fertility, pregnancy,...
-
在临床三期AirFLO试验中，爱司韦™与安慰剂相比显著降低症状评分（p=0.002）及病毒载量（p=0.006），达到试验主要终点和关键次要终点 RSV感染是五岁以下儿童因病毒感染而住院及死亡的首要因素爱司韦™是全球首个成功在儿童患者人群中完成关键性三期临床研究的RSV抗病毒药物爱司韦™计划于2022年年中向中国监管机构提交新药上市申请 上海, April 07, 2022 (GLOBE...
-
在臨床三期AirFLO試驗中，愛司韋™與安慰劑相比顯著降低症狀評分（p=0.002）及病毒載量（p=0.006），達到試驗主要終點和關鍵次要終點 RSV感染是五歲以下兒童因病毒感染而住院及死亡的首要因素愛司韋™是全球首個成功在兒童患者人群中完成關鍵性三期臨床研究的RSV抗病毒藥物愛司韋™計畫於2022年年中向中國監管機構提交新藥上市申請 上海, April 07, 2022 ...
-
Phase 3 AirFLO study with ziresovir met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with...